



PRESS RELEASE

Aptar Pharma and i2c Pharmaceutical Services Announce Partnership for Next Generation Propellant Dispersible Tablet pMDI Technology

*Agreement gives Aptar Pharma an exclusive option for a worldwide license
for i2c's patented Respitab® technology*

Crystal Lake, Illinois and Cardiff, United Kingdom, October 21, 2021 - Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, and i2c Pharmaceutical Services, a leading service provider for the development of pharmaceutical formulations, today announced an exclusive partnership to co-develop and promote i2c's patented pressurized metered dose inhaler (pMDI) technology, Respitab®.

As part of the agreement, Aptar Pharma, who is the market leader in pulmonary drug delivery device solutions for the management and treatment of asthma and chronic obstructive pulmonary disease (COPD), will evaluate the commercial applications for Respitab, in particular for new, lower global warming potential (GWP) propellants.

Respitab is a propellant dispersible tablet that eliminates the need for a complex mixing process used in standard pMDI manufacturing. A patented, innovative platform which enables the transition to the next generation of pMDIs for a range of active pharmaceutical ingredients (APIs) and combination products, Respitab is also a cost-effective approach for new chemical entity (NCE) and generic pMDI products, simplifying the manufacturing process for HFC 152a and other propellants.

Suitable for APIs with different physicochemical properties, Respitab has highly efficient aerosol properties and dose uniformity characteristics. Respitab's other advantages include reduced waste and API losses, as well as ease of scalability.



PRESS RELEASE

Howard Burnett, Vice President Global Pulmonary Category, Aptar Pharma commented, “We are pleased to partner with i2c on this novel technology which brings many benefits to the filling of metered dose inhalers. This development further enhances Aptar Pharma’s industry-leading portfolio of devices, which, combined with our broad spectrum of Aptar Pharma Services, allows us to offer end-to-end support to our clients and partners.”

“We are excited by this partnership with Aptar Pharma which brings together substantial synergies to provide a lower GWP product range to patients in the pMDI format, the most popular inhaler type across the globe,” added Glyn Taylor, CSO of i2c Pharmaceutical Services.

About Aptar Pharma

Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar's innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

About i2c

i2c Pharmaceutical Services, as a part of Cardiff Scintographics Limited, is a leading independent service provider to the global pharma, medical technology companies and emerging clients for the development of pharmaceutical formulations and inhaler devices from its facilities in Cardiff, Wales. Established almost 30 years ago, i2c have built a wealth of experience and knowledge in the area of respiratory pharmaceutical formulation, device



PRESS RELEASE

development and research. i2c have fulfilled studies for more than 50 different pharma companies. For more information, visit www.i2cpharm.co.uk.

#

Media Contacts:

Aptar Pharma

Carolyn Penot

+33 1 39 17 20 38

carolyn.penot@aptar.com

i2c Pharmaceutical Services

Glyn Taylor

+44 29 2075 7865

glyn@i2cpharm.co.uk